Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
This trial is conducted globally. The aim of this trial is to investigate dose-finding of semaglutide administered subcutaneously once daily versus placebo and liraglutide in subjects with type 2 diabetes
Inclusion Criteria:
Exclusion Criteria:
Saint Stefan, 8511, Austria
Pohlheim, 35415, Germany
Saint Ingbert-Oberwürzbach, 66386, Germany
Klang, Selangor, 41200, Malaysia
Middleburg, Mpumalanga 1055, South Africa
Devon, EX2 5DW, United Kingdom
Harrogate, North Yorkshire, HG2 7SX, United Kingdom